問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


MacKay Memorial Hospital (在職)

Division of Cardiovascular Diseases

Division of Cardiovascular Diseases

MacKay Memorial Hospital (在職)

Division of Cardiovascular Diseases

Division of Cardiovascular Diseases

Division of Occupational Medicine

馬偕紀念醫院佳生臨床藥理試驗中心_佳永生技股份有限公司

Division of Cardiovascular Diseases

Tri-Service General Hospital

Division of Psychiatry

更新時間：2023-09-19

陳俊延
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

12Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳俊延

List

25Cases

2019-05-02 - 2026-01-17

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-04-13 - 2027-05-05

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2023-03-01 - 2027-02-28

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Recruiting17Sites

2013-11-01 - 2016-06-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2012-12-01 - 2019-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2014-11-01 - 2018-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2025-12-01 - 2029-01-12

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

2025-12-01 - 2029-01-12

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

2022-10-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Not yet recruiting11Sites

2017-02-01 - 2019-04-30

Phase III

A Phase III Multi-Center, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Clinical Trial in High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects With Coronary Artery Disease (CAD) to Determine Whether Bromodomain Extraterminal Domain (BET) Inhibition Treatment With RVX000222 Increases the Time to Major Adverse Cardiovascular Events (MACE)

  • Condition/Disease

    High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects With Coronary Artery Disease (CAD)

  • Test Drug

    RVX000222

Participate Sites
14Sites

Terminated14Sites

江晨恩
Taipei Veterans General Hospital

謝宜璋
Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB